Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial.
Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied.To investigate whether MBCT with discontinuation of mADM is non-inferior to MBCT+mADM.A multicentre randomis...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Maney Publishing
2016
|
| _version_ | 1797088477185048576 |
|---|---|
| author | Huijbers, M Spinhoven, P Spijker, J Ruhé, H van Schaik, D van Oppen, P Nolen, W Ormel, J Kuyken, W van der Wilt, G Blom, M Schene, A Rogier, A Donders, T Speckens, A |
| author_facet | Huijbers, M Spinhoven, P Spijker, J Ruhé, H van Schaik, D van Oppen, P Nolen, W Ormel, J Kuyken, W van der Wilt, G Blom, M Schene, A Rogier, A Donders, T Speckens, A |
| author_sort | Huijbers, M |
| collection | OXFORD |
| description | Mindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied.To investigate whether MBCT with discontinuation of mADM is non-inferior to MBCT+mADM.A multicentre randomised controlled non-inferiority trial (ClinicalTrials.gov:NCT00928980). Adults with recurrent depression in remission, using mADM for 6 months or longer (n= 249), were randomly allocated to either discontinue (n= 128) or continue (n= 121) mADM after MBCT. The primary outcome was depressive relapse/recurrence within 15 months. A confidence interval approach with a margin of 25% was used to test non-inferiority. Key secondary outcomes were time to relapse/recurrence and depression severity.The difference in relapse/recurrence rates exceeded the non-inferiority margin and time to relapse/recurrence was significantly shorter after discontinuation of mADM. There were only minor differences in depression severity.Our findings suggest an increased risk of relapse/recurrence in patients withdrawing from mADM after MBCT. |
| first_indexed | 2024-03-07T02:50:39Z |
| format | Journal article |
| id | oxford-uuid:ad928b81-d111-4679-8eba-9d2024c7541c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:50:39Z |
| publishDate | 2016 |
| publisher | Maney Publishing |
| record_format | dspace |
| spelling | oxford-uuid:ad928b81-d111-4679-8eba-9d2024c7541c2022-03-27T03:36:30ZDiscontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ad928b81-d111-4679-8eba-9d2024c7541cEnglishSymplectic Elements at OxfordManey Publishing2016Huijbers, MSpinhoven, PSpijker, JRuhé, Hvan Schaik, Dvan Oppen, PNolen, WOrmel, JKuyken, Wvan der Wilt, GBlom, MSchene, ARogier, ADonders, TSpeckens, AMindfulness-based cognitive therapy (MBCT) and maintenance antidepressant medication (mADM) both reduce the risk of relapse in recurrent depression, but their combination has not been studied.To investigate whether MBCT with discontinuation of mADM is non-inferior to MBCT+mADM.A multicentre randomised controlled non-inferiority trial (ClinicalTrials.gov:NCT00928980). Adults with recurrent depression in remission, using mADM for 6 months or longer (n= 249), were randomly allocated to either discontinue (n= 128) or continue (n= 121) mADM after MBCT. The primary outcome was depressive relapse/recurrence within 15 months. A confidence interval approach with a margin of 25% was used to test non-inferiority. Key secondary outcomes were time to relapse/recurrence and depression severity.The difference in relapse/recurrence rates exceeded the non-inferiority margin and time to relapse/recurrence was significantly shorter after discontinuation of mADM. There were only minor differences in depression severity.Our findings suggest an increased risk of relapse/recurrence in patients withdrawing from mADM after MBCT. |
| spellingShingle | Huijbers, M Spinhoven, P Spijker, J Ruhé, H van Schaik, D van Oppen, P Nolen, W Ormel, J Kuyken, W van der Wilt, G Blom, M Schene, A Rogier, A Donders, T Speckens, A Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title | Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title_full | Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title_fullStr | Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title_full_unstemmed | Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title_short | Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial. |
| title_sort | discontinuation of antidepressant medication after mindfulness based cognitive therapy for recurrent depression randomised controlled non inferiority trial |
| work_keys_str_mv | AT huijbersm discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT spinhovenp discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT spijkerj discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT ruheh discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT vanschaikd discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT vanoppenp discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT nolenw discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT ormelj discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT kuykenw discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT vanderwiltg discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT blomm discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT schenea discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT rogiera discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT donderst discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial AT speckensa discontinuationofantidepressantmedicationaftermindfulnessbasedcognitivetherapyforrecurrentdepressionrandomisedcontrollednoninferioritytrial |